Ghrelin immunoreactivity in human plasma is suppressed by somatostatin.
OBJECTIVE
Ghrelin was recently identified as a specific endogenous ligand for the growth hormone secretagogue receptor (GHS-R). This new hormone was isolated from rat and human stomach and was reported to circulate in human plasma, but the regulation and physiological significance of ghrelin in humans have not been clarified. The present study was undertaken to test the following hypotheses: (1) prolonged fasting, which is known to stimulate GH secretion, is associated with changes in ghrelin immunoreactivity; (2) somatostatin in the systemic circulation regulates ghrelin secretion; and (3) GH affects ghrelin levels.


METHODS
The study population included normal subjects investigated on three occasions (fasting alone, fasting and somatostatin infusion +/- GH); GH-deficient adults investigated after 12 and 36 h of fasting +/- GH, as well as patients with active acromegaly before and after somatostatin analogue treatment.


RESULTS
Somatostatin infusion lowered ghrelin levels 70-80% (P < 0.0001), whereas continued fasting +/- GH did not significantly affect ghrelin levels. In active acromegaly, suppression of plasma ghrelin levels was recorded after a single subcutaneous octreotide injection as well as during prolonged administration of slow-release octreotide.


CONCLUSIONS
(1) Amplification of GH release during prolonged fasting is not caused by an increase in ghrelin immunoreactivity, (2) systemic somatostatin suppresses plasma ghrelin levels independently of GH status, and (3) the feasibility of measuring ghrelin in the circulation provides an opportunity for studying the interaction between hormones and nutrition.
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy; D000328:Adult; D000368:Aged; D005215:Fasting / Q000097:blood; D054439:Ghrelin; D006728:Hormones / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000172:deficiency / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use; D036361:Peptide Hormones / Q000097:blood* / Q000187:drug effects / Q000276:immunology; D013004:Somatostatin / Q000494:pharmacology*
D054439:Ghrelin; D006728:Hormones; D036361:Peptide Hormones; D019382:Human Growth Hormone; D013004:Somatostatin; D015282:Octreotide